rhodomycin

anthracycline antibiotic; antibiotic substance from Streptomyces strain JA 8467; RN given refers to cpd with unknown MF; structure

Also Known As:

beta-rhodomycin II; beta-rhodomycin S 1b; beta-rhodomycin S 3; beta-rhodomycin S 4; epsilon-rhodomycin; Rhodomycin

Networked: 4 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthacenes
        Anthracyclines: 9423
        rhodomycin: 4
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthacenes
    - Anthracyclines: 9423
      - rhodomycin: 4
Carbohydrates: 22023
- Glycosides: 2119
  - Aminoglycosides: 5131
    - Anthracyclines: 9423
      - rhodomycin: 4

Experts

1.	Chang, Gee-Chen: 1 article (09/2015)
2.	Chen, Huei-Wen: 1 article (09/2015)
3.	Chen, Jeremy J W: 1 article (09/2015)
4.	Chen, Min-Hsuan: 1 article (09/2015)
5.	Lai, Yi-Hua: 1 article (09/2015)
6.	Lin, Sheng-Yi: 1 article (09/2015)
7.	Lin, Sih-Yin: 1 article (09/2015)
8.	Wong, Yung-Hao: 1 article (09/2015)
9.	Yang, Chih-Hsin: 1 article (09/2015)
10.	Yu, Sung-Liang: 1 article (09/2015)

Related Diseases

1.	Muscle Weakness 05/01/1991 - "The therapeutic efficacy and toxic effect of daunomycin (Dm), an antibiotic of the rhodomycin group, was evaluated in murine experimental autoimmune MG. Low dosage Dm treatment effectively prevented the development of muscle weakness and its associated electrophysiological abnormality, without inducing detectable toxicity and global immunosuppression."
2.	Neoplasms (Cancer) 09/22/2015 - "Furthermore, rhodomycin A significantly suppressed cancer cell proliferation, migration, invasion, and clonogenicity in vitro and tumour growth in vivo. " 10/01/1988 - "Treatment of tumors in vivo with doxorubicin at doses below the maximally tolerated dose in mice resulted in multiple log cell kill as measured in vitro or in vivo, whereas rhodomycin B was cytotoxic only at dose levels exceeding its maximally tolerated dose. "
3.	Pancreatic Neoplasms (Pancreatic Cancer) 03/01/1990 - "The corresponding p-maleimidobenzoyl derivatives of beta-rhodomycin I, N,N-dimethyldaunorubicin, and rodorubicin have been attached to thiol groups of the hinge region of reduced monoclonal antibody BW 494/32, directed against a pancreatic cancer associated glycoprotein antigen, resulting in MoAb BW 494/32 conjugates, carrying 4.8-6.8 mol of cytotoxic residues/mol of MoAb. "
4.	Lung Neoplasms (Lung Cancer) 09/22/2015 - "Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways." 09/22/2015 - "Our data also reveal that the inhibitory effect of rhodomycin A on lung cancer progression may act through suppressing the Src-related multiple signalling pathways, including PI3K, JNK, Paxillin, and p130cas. "
5.	Adenocarcinoma of Lung 09/22/2015 - "In addition, rhodomycin A rendered gefitinib-resistant lung adenocarcinoma cells more sensitive to gefitinib treatment, implying a synergistic effect of the combination therapy. "

Related Drugs and Biologics

1.	Daunorubicin (Cerubidine)
2.	Anti-Bacterial Agents (Antibiotics)
3.	Paxillin
4.	Sulfhydryl Compounds (Thiols)
5.	Glycoproteins (Glycoprotein)
6.	Doxorubicin (Adriamycin)
7.	Antigens
8.	Monoclonal Antibodies
9.	Gefitinib (Iressa)
10.	rodorubicin

Related Therapies and Procedures

1.	Therapeutics